StreetInsider.com News Articles

NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting

Fri, 28 Aug 2026 10:08:14 -0400

NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline results from its NEO100-01 Phase 2a clinical study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, according to a paid editorial communication issued by 24/7 Market News, which is compensated by NTHI for news coverage.

The company reported a six-month progression-free survival rate of 48.9%, exceeding the prespecified benchmark of 20%, with a p-value of 0.0047. Median overall survival was reported at 26.09 months, and 86.7% of patients were alive at six months. Five of the 24 enrolled patients remained on treatment at the time of reporting, including

NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting

Fri, 28 Aug 2026 10:08:14 -0400

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

Fri, 28 Aug 2026 10:07:00 -0400

DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.

On August 12, NeOnc reported positive topline results from the NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The company reported 48.9% six-month progression-free survival, substantially above the prespecified 20% benchmark,

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

Fri, 28 Aug 2026 10:07:00 -0400

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

Fri, 28 Aug 2026 10:07:00 -0400

NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger

Fri, 28 Aug 2026 10:07:00 -0400

NeOnc’s Clinical Story Is Now the Main Event

Wed, 26 Aug 2026 09:39:00 -0400

DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens if NEO100’s clinical results translate into a viable regulatory pathway for a difficult-to-treat form of brain cancer?

On August 12, NeOnc reported positive topline Phase 2a results from its NEO100-01 study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint, with 48.9% six-month progression-free survival versus a pre-specified 20% benchmark, producing a reported p-value of

NeOnc’s Clinical Story Is Now the Main Event

Wed, 26 Aug 2026 09:39:00 -0400

NeOnc’s Clinical Story Is Now the Main Event

Wed, 26 Aug 2026 09:39:00 -0400

NeOnc’s Clinical Story Is Now the Main Event

Wed, 26 Aug 2026 09:39:00 -0400

Form 8-K/A NEONC TECHNOLOGIES HOLDI For: Jun 27

Fri, 21 Aug 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260821/26960951.html

Form 8-K/A NEONC TECHNOLOGIES HOLDI For: Jun 27

Fri, 21 Aug 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260821/26960951.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Aug 18 Filed by: CHEN THOMAS C

Thu, 20 Aug 2026 21:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26957592.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Aug 18 Filed by: CHEN THOMAS C

Thu, 20 Aug 2026 21:16:00 -0400

si-local-file:///var/storage/secattach/20260820/26957592.html

Form 4/A NEONC TECHNOLOGIES HOLDI For: Apr 10 Filed by: CHEN THOMAS C

Thu, 20 Aug 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260820/26957590.html

Form 4/A NEONC TECHNOLOGIES HOLDI For: Apr 10 Filed by: CHEN THOMAS C

Thu, 20 Aug 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260820/26957590.html

Form 8-K NEONC TECHNOLOGIES HOLDI For: Aug 14

Thu, 20 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26953840.html

Form 8-K NEONC TECHNOLOGIES HOLDI For: Aug 14

Thu, 20 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260820/26953840.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Apr 09 Filed by: CHEN THOMAS C

Tue, 18 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260818/26944374.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Apr 09 Filed by: CHEN THOMAS C

Tue, 18 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260818/26944374.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Aug 18 Filed by: Heshmatpour Amir F

Tue, 18 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26943535.html

Form 4 NEONC TECHNOLOGIES HOLDI For: Aug 18 Filed by: Heshmatpour Amir F

Tue, 18 Aug 2026 14:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26943535.html

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t

Tue, 18 Aug 2026 10:18:00 -0400

DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Amir Heshmatpour, is continuing to buy shares on the open market.

According to the Form 4 transaction information provided by the company’s latest filing, Heshmatpour purchased 12,000 NTHI shares on August 14 at an average price of $3.7883 and another 3,000 shares on August 17 at an average price of $4.3733. Combined, the 15,000 shares represent roughly $58,600 of additional open-market buying, at a weighted average price of

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t

Tue, 18 Aug 2026 10:18:00 -0400

NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t

Tue, 18 Aug 2026 10:18:00 -0400